肺癌驱动基因研究总结.ppt

NSCLC驱动基因 ROS1融合基因 ROS1临床病例 31岁，男性，非吸烟 EGFR 野生型；ALK(—) 一线吉非替尼治疗无效 口服Crizotinib 8周后高度PR ROS fusion: FISH ROS fusion: IHC Bergethon K, et al. J Clin Oncol 2012; 30:863-870. 肺腺癌，发生率1% ALKinhibitor有效 Crizotinib在ROS1 NSCLC中的临床活性 Abstract No. 7508 , 2012 ASCO Lan et al, Nat Gen 2012 NSCLC驱动基因 KRAS CR, complete response; PR, partial response; SD, stable diseasePD, progressive disease; DoR, duration of response; APF6, alive and progression-free at 6 months ?Fisher’s exact 2-sided mid p value ?1-sided p value *11 confirmed, 5 unconfirmed §One patient was classed as non-evaluable due to non?evaluabl